ANKE BIO(SZ:300009) Xin Lang Cai Jing·2025-09-09 03:39Core Viewpoint - Anke Biological has experienced a decline in stock price recently, with a year-to-date increase of 28.47% but a 6.10% drop in the last five trading days [1][2] Company Overview - Anke Biological, established on September 28, 2000, and listed on October 30, 2009, is located in Hefei, Anhui Province. The company specializes in research, development, production, and sales of biotechnological products, including cell engineering, gene engineering, gene testing, and precision medicine [1] - The main revenue sources for Anke Biological are gene engineering drugs (88.24%), topical patches (11.67%), and other supplementary products (0.09%) [1] Financial Performance - For the first half of 2025, Anke Biological reported a revenue of 1.292 billion yuan, a year-on-year decrease of 0.51%, and a net profit attributable to shareholders of 367 million yuan, down 11.92% year-on-year [2] - Since its A-share listing, Anke Biological has distributed a total of 2.662 billion yuan in dividends, with 1.252 billion yuan distributed in the last three years [3] Shareholder Structure - As of June 30, 2025, Anke Biological had 65,700 shareholders, a decrease of 2.17% from the previous period, with an average of 18,598 circulating shares per person, an increase of 2.22% [2] - The top ten circulating shareholders include Hong Kong Central Clearing Limited, which holds 20.7916 million shares (an increase of 7.341 million shares), and other notable shareholders such as the China National Securities Bio-Medical Index A and the Southern CSI 1000 ETF [3]